Publications by authors named "F Nader"
Objective: To compare VR simulations with other training methods regarding improvements in objective assessment scores and task completion times.
Method: A database search was conducted on 20 May 2024 across Central, MEDLINE, EMBASE, Web of Science, and Scopus. Included were randomised controlled trials comparing VR simulations to other training methods, assessing objective scores and task times.
Background And Aims: Lacking access to quality food may increase the risk of metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated associations between food environment factors (food deserts and food swamps) and MASLD-related mortality across the United States.
Methods: MASLD-related deaths were obtained from the National Vital Statistics System (2016-2020) and food environment factors from Food Environment Atlas.
Article Synopsis
- Several scientific associations suggest using a combination of non-invasive tests to identify high-risk patients for metabolic dysfunction-associated steatohepatitis (MASLD), but the cost-effectiveness of these methods is not yet known.
- A cost-utility model was created to evaluate the cost-effectiveness of various screening strategies for high-risk MASLD patients, particularly those with type 2 diabetes or obesity, comparing the use of initial and secondary testing methods.
- The study found that while all screening strategies involve additional costs, they lead to significant long-term savings and are deemed cost-effective, reinforcing the recommendation to implement these screening methods in primary care settings.
Article Synopsis
- * Two global surveys, one for specialists and another for non-specialists, assessed awareness and knowledge regarding MASLD/NAFLD, revealing that practice guidelines were the primary source of information for physicians.
- * Results showed that while specialists (hepatologists and gastroenterologists) had similar knowledge levels, endocrinologists outperformed primary care providers in knowledge across multiple domains, highlighting a significant knowledge gap that needs to be addressed through better education.
Article Synopsis
- Resmetirom, a thyroid-hormone receptor-β agonist, has been approved for treating metabolic dysfunction-associated steatohepatitis (MASH), and its impact on health-related quality of life (HRQL) was studied in this clinical trial.
- In a 54-month double-blind trial with nearly 1,000 patients, those receiving resmetirom (80 mg or 100 mg) showed significant improvements in various HRQL measures compared to a placebo group, particularly in the Worry domain of the Chronic Liver Disease Questionnaire (CLDQ-NAFLD).
- The study concluded that patients with MASH/NASH who improved their fibrosis or resolved MASH experienced notable HRQL enhancements, indicating that resmeti